Compare Medtronic PLC (MDT) vs Nvidia Corp (NVDA) Price & Performance

Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.

The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.

NVIDIA (NVDA) trades at $205.95, up 1.55% on the day, with a neutral technical signal. The stock exhibits exceptional fundamental strength, with revenue surging to $130.50B in 2025 and net income margin reaching 62.97%. Recent quarterly earnings have consistently exceeded expectations, and analyst consensus remains strongly bullish with a $325.86 price target, though some institutional investors have recently trimmed positions.

The outlook is supported by dominant positioning in AI infrastructure, with revenue growth expected to continue. Key risks include peak AI spending concerns, intensifying competition, and high valuation multiples. The stock's performance is closely tied to the sustainability of the AI investment cycle and its ability to maintain technological leadership.